Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Salvetti

Showing results (41-50 of 231) with videos related to

Pageof 24
Sort By:
Immunology and Cell Biology|June 7, 2016
Interferon-β therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosisFabiana Rizzo, Elena Giacomini, Rosella Mechelli, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 9, 2022
Researching COVID-19 in progressive MS requires a globally coordinated, multi-disciplinary and multi-stakeholder approach-perspectives from the International Progressive MS AlliancePaola Zaratin, Brenda Banwell, Timothy Coetzee, et al.
Frontiers in Neurology|April 1, 2022
Secondary Prevention in Radiologically Isolated Syndromes and Prodromal Stages of Multiple SclerosisMaria Pia Amato, Nicola De Stefano, Matilde Inglese, et al.
Aging Clinical and Experimental Research|July 19, 2020
The tolerability, safety and efficacy of safinamide in elderly Parkinson's disease patients: a retrospective studyDomiziana Rinaldi, Edoardo Bianchini, Michela Sforza, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|October 17, 2020
Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory studyDomiziana Rinaldi, Michela Sforza, Francesca Assogna, et al.
Frontiers in Neurology|August 1, 2022
Bridging Therapies With Injectable Immunomodulatory Drugs in the Management of Multiple Sclerosis: A Delphi Survey of an Italian Expert Panel of NeurologistsGirolama Alessandra Marfia, Diego Centonze, Marco Salvetti, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 24, 2024
Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in a real-world setting: Final results from the Plegridy Observational ProgramMarco Salvetti, Sibyl Wray, Gereon Nelles, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|March 21, 2024
Co-existence of Myelin Oligodendrocyte Glycoprotien Antibody-associated Disease (MOGAD) and Spinocerebellar Ataxia type 1 (SCA1): A case reportMartina Nasello, Valeria Zancan, Roberta Reniè, et al.
Annals of Clinical and Translational Neurology|October 31, 2014
Noise in multiple sclerosis: unwanted and necessaryIsabella Bordi, Vito A G Ricigliano, Renato Umeton, et al.
Brain : a Journal of Neurology|April 17, 2014
Shared environmental effects on multiple sclerosis susceptibility: conflicting evidence from twin studiesCorrado Fagnani, Vito A G Ricigliano, Maria Chiara Buscarinu, et al.
Pageof 24

Showing results (41-50 of 231) with videos related to

Sort By:
Pageof 24
Immunology and Cell Biology|June 7, 2016
Interferon-β therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosisFabiana Rizzo, Elena Giacomini, Rosella Mechelli, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 9, 2022
Researching COVID-19 in progressive MS requires a globally coordinated, multi-disciplinary and multi-stakeholder approach-perspectives from the International Progressive MS AlliancePaola Zaratin, Brenda Banwell, Timothy Coetzee, et al.
Frontiers in Neurology|April 1, 2022
Secondary Prevention in Radiologically Isolated Syndromes and Prodromal Stages of Multiple SclerosisMaria Pia Amato, Nicola De Stefano, Matilde Inglese, et al.
Aging Clinical and Experimental Research|July 19, 2020
The tolerability, safety and efficacy of safinamide in elderly Parkinson's disease patients: a retrospective studyDomiziana Rinaldi, Edoardo Bianchini, Michela Sforza, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|October 17, 2020
Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory studyDomiziana Rinaldi, Michela Sforza, Francesca Assogna, et al.
Frontiers in Neurology|August 1, 2022
Bridging Therapies With Injectable Immunomodulatory Drugs in the Management of Multiple Sclerosis: A Delphi Survey of an Italian Expert Panel of NeurologistsGirolama Alessandra Marfia, Diego Centonze, Marco Salvetti, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 24, 2024
Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in a real-world setting: Final results from the Plegridy Observational ProgramMarco Salvetti, Sibyl Wray, Gereon Nelles, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|March 21, 2024
Co-existence of Myelin Oligodendrocyte Glycoprotien Antibody-associated Disease (MOGAD) and Spinocerebellar Ataxia type 1 (SCA1): A case reportMartina Nasello, Valeria Zancan, Roberta Reniè, et al.
Annals of Clinical and Translational Neurology|October 31, 2014
Noise in multiple sclerosis: unwanted and necessaryIsabella Bordi, Vito A G Ricigliano, Renato Umeton, et al.
Brain : a Journal of Neurology|April 17, 2014
Shared environmental effects on multiple sclerosis susceptibility: conflicting evidence from twin studiesCorrado Fagnani, Vito A G Ricigliano, Maria Chiara Buscarinu, et al.
Pageof 24